<DOC>
	<DOCNO>NCT01122927</DOCNO>
	<brief_summary>This open-label study consist screen period , conversion/titration phase ( Phase 1 ) , open-label treatment phase ( Phase 2 ) , follow-up period . The study enroll new subject ( hereafter refer `` de novo '' subject ) schizophrenia , bipolar I disorder , manic mixed episode without psychotic feature , rollover subject schizophrenia 31-09-266 ( hereafter refer `` Study 266 '' ) . All de novo subject must enter screen period study . Subjects screen require go Phase 1 complete Phase 2 baseline visit prior participation Phase 2 . Study Design : Treatment , Single Group Assignment , Open Label , Active Control , Safety/Efficacy Study</brief_summary>
	<brief_title>Safety Tolerability Aripiprazole Adolescents With Schizophrenia Children Adolescents With Bipolar I Disorder , Manic Mixed Episode With Without Psychotic Features .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects 1317 year old ( Schizophrenia ) ; Subjects 1017 year old ( Bipolar manic mixed episode ) * [ *Bulgaria enroll Schizophrenia subject . ] Subjects current diagnosis schizophrenia , history illness ( diagnosis symptom ) least 6 month prior screen ( per subject , family , healthcare provider , previous medical record ) . Subjects current diagnosis bipolar I disorder , manic mixed episode without psychotic feature ( diagnosis symptom ) experience symptom least 1 week prior screen . * [ *These subject eligible enroll Bulgaria ] Subjects show previous response antipsychotic treatment ( clozapine ) resistant treatment antipsychotic . Subjects currently treat oral antipsychotic clozapine , resistant treatment antipsychotic . Inpatient outpatient status , exception acute hospitalization due psychiatric reason time screen Phase 2 . All subject : diagnosis schizoaffective disorder , autism , pervasive developmental disorder ( PDD ) , OCD , PTSD . Subjects schizophrenia : current major depressive episode . Subjects bipolar manic mixed episode : presenting clinical picture and/or history consistent diagnosis bipolar II disorder bipolar disorder otherwise specify . Subjects delirium , dementia , amnesia cognitive disorder ; subject psychotic symptom well account another general medical condition ( ) direct effect substance ( i.e. , medication , illicit drug use , etc. ) . Subjects neurological disorder , exception Tourette 's syndrome . Subjects experience major depressive episode time screen subject diagnose bipolar I disorder mixed episode . Subjects currently receive clozapine receive clozapine time past ineligible entry study . Subjects meet DSMIVTR criterion substance dependence ( include alcohol benzodiazepine , exclude caffeine nicotine ) within past 180 day prior screen . Subjects epilepsy , history seizure ( except single childhood febrile seizure posttraumatic seizure ) , history severe head trauma stroke , history current evidence unstable medical condition . Subjects history subclinical hypothyroidism ( TSH ≥ 4.0 mIU/L ) , know hypothyroidism , hyperthyroidism ( unless condition stabilize medication least 90 day prior entry Phase 1 Phase 2 ) . Subjects medical history uncontrolled diabetes , labile unstable diabetes ( brittle diabetes ) , newly diagnose diabetes , clinically significant abnormal blood glucose level ( define fast blood glucose ≥ 125 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>adolescent</keyword>
	<keyword>bipolar</keyword>
</DOC>